

# Index

|                               |                     |
|-------------------------------|---------------------|
| <b>ACKNOWLEDGEMENTS .....</b> | <b><i>I</i></b>     |
| <b>INDEX.....</b>             | <b><i>V</i></b>     |
| <b>FIGURE LIST.....</b>       | <b><i>XI</i></b>    |
| <b>TABLE LIST.....</b>        | <b><i>XV</i></b>    |
| <b>EQUATION LIST .....</b>    | <b><i>XVII</i></b>  |
| <b>ABSTRACT .....</b>         | <b><i>XIX</i></b>   |
| <b>RESUMEN.....</b>           | <b><i>XXIII</i></b> |
| <b>RESUM.....</b>             | <b><i>XXVII</i></b> |
| <b>GLOSSARY .....</b>         | <b><i>XXXI</i></b>  |

|  |           |
|--|-----------|
| <b>SECTION 1. GENERAL INTRODUCTION</b>   | <b>1</b>  |
| <b>Chapter 1</b>   | <b>3</b>  |
| <b>General introduction</b>  | <b>3</b>  |
| <b>1.1. Disease modeling and tissue engineering</b>                                  | <b>3</b>  |
| <b>1.2. The bone marrow microenvironment</b>   | <b>6</b>  |
| 1.2.1. Hematopoietic stem cells (HSC) and Hematopoiesis                              | 7         |
| 1.2.2. HSCs location in healthy bone marrow microenvironment                         | 11        |
| 1.2.3. Bone marrow resident cells  | 13        |
| 1.2.3.1. Mesenchymal stem cells  | 13        |
| 1.2.3.2. Bone cells  | 14        |
| 1.2.3.3. Endothelial cells   | 15        |
| 1.2.3.4. Neurons and non-myelinating Schwann cells                                   | 16        |
| 1.2.3.5. Relevant mediators of intercellular communication                           | 17        |
| 1.2.3.6. Non cellular elements   | 20        |
| 1.2.3.7. Extracellular matrix  | 20        |
| 1.2.4. Hematological malignancies and their relationship with their microenvironment | 21        |
| 1.2.4.1. Competition between HSCs and tumor cells in the BMN                         | 23        |
| 1.2.4.2. BMN as predisposition factor for tumor initiation                           | 23        |
| 1.2.4.3. BMN remodelling and BMN-forming cells reprogramming by malignant cells      | 25        |
| 1.2.4.4. Transformed BMN favours malignancy  | 25        |
| <b>1.3. Multiple myeloma</b>   | <b>26</b> |
| 1.3.1. Signaling pathways that sustain MM cells abnormal proliferation               | 28        |

|  |   |           |
|--|---|-----------|
| 1.3.1.1  | The NFκB pathway.....   | 29        |
| 1.3.1.2.   | The PI3K/Akt/mTOR pathway.....                                    | 31        |
| 1.3.1.3.   | The Ras/Raf/MEK/Erk pathway .....                                 | 32        |
| 1.3.1.4.   | The JAK/STAT pathway.....   | 33        |
| 1.3.1.5.   | The Wnt/β-catenin pathway .....                                   | 34        |
| 1.3.2.   | Multiple myeloma treatments.....                                  | 35        |
| 1.3.2.1.   | Dexamethasone.....  | 36        |
| 1.3.2.2.   | Bortezomib .....  | 36        |
| 1.3.3.   | Drug resistance in multiple myeloma .....                         | 37        |
| 1.3.3.1.   | Tumor microenvironment .....                                      | 38        |
| 1.3.3.2.   | Extracellular matrix molecules with relevant roles in CAM-DR..... | 40        |
| <b>1.4.</b>  | <b>Modelling Multiple myeloma.....</b>                            | <b>42</b> |
| 1.4.1.   | Models based on hydrogels.....                                    | 42        |
| 1.4.2.   | Models based on scaffolds .....                                   | 44        |
| 1.4.3.   | Models based on microfluidics and bioreactors.....                | 45        |
| <b>Chapter 2.</b>  | <b>.....</b>  | <b>49</b> |
| <b>Hypothesis and objectives</b>                                       | <b>.....</b>  | <b>49</b> |
| 2.1.   | Hypothesis.....   | 49        |
| 2.2.   | Objectives.....   | 51        |
| <b>SECTION 2. EXPERIMENTAL CHAPTERS</b>                                | <b>.....</b>  | <b>43</b> |
| <b>Chapter 3.</b>  | <b>.....</b>  | <b>55</b> |
| <b>Microspheres: synthesis, characterization and functionalization</b> | <b>.....</b>  | <b>55</b> |

|  |            |
|--|------------|
| <b>3.1.Summary .....</b>   | <b>55</b>  |
| <b>3.2.Introduction .....</b>  | <b>56</b>  |
| 3.2.1. Emulsion methods for microsphere production .....               | 56         |
| 3.2.2. Techniques for microsphere’s functionalization .....            | 58         |
| 3.2.2.1. Physical adsorption.....                                      | 58         |
| 3.2.2.2. Covalent grafting .....                                       | 59         |
| 3.2.2.3. Layer- by-layer assembly .....                                | 61         |
| <b>3.3.Materials and methods.....</b>                                  | <b>63</b>  |
| 3.3.1. Microsphere’s production.....                                   | 63         |
| 3.3.1.1. Acrylates-based microspheres.....                             | 63         |
| 3.3.1.2. Cytodex 1 microspheres.....                                   | 65         |
| 3.3.2. Microsphere’s functionalization .....                           | 66         |
| 3.3.2.1. Acrylates-based microspheres.....                             | 66         |
| 3.3.2.2. Cytodex 1 microspheres .....                                  | 68         |
| 3.3.3. Microsphere’s characterizations.....                            | 71         |
| 3.3.3.1. Acrylates-based microspheres.....                             | 71         |
| 3.3.3.2. Cytodex 1 microspheres .....                                  | 74         |
| <b>3.4.Results and discussion .....</b>                                | <b>75</b>  |
| 3.4.1. Synthesis and functionalization of acrylates microspheres ..... | 75         |
| 3.4.1.1. Synthesis and characterization of acrylates microspheres..... | 75         |
| 3.4.1.2. Functionalization of acrylates microspheres .....             | 86         |
| 3.4.2. Functionalization of Cytodex 1 microspheres .....               | 91         |
| <b>3.5.Conclusions .....</b>   | <b>109</b> |
| <b>Chapter 4.....</b>  | <b>111</b> |

***The Microgel as 3D culture system for Multiple myeloma cell lines...111***

|  |            |
|--|------------|
| <b>4.1. Summary .....</b>  | <b>111</b> |
| <b>4.2. Introduction .....</b>   | <b>112</b> |
| 4.2.1. Microspheres as 3D systems for cell culture .....                     | 112        |
| 4.2.2. Multiple myeloma cell lines as in vitro models. ....                  | 115        |
| <b>4.3. Materials and methods.....</b>                                       | <b>116</b> |
| 4.3.1. Acrylates-based microsphere carboxyl group blockade.....              | 116        |
| 4.3.2. Microsphere sterilization.....  | 116        |
| 4.3.2.1. Acrylates-based microspheres .....                                  | 116        |
| 4.3.2.2. Cytodex 1 microspheres .....  | 117        |
| 4.3.3. Cell lines.....   | 117        |
| 4.3.4. Development of 3D microgel cultures.....                              | 117        |
| 4.3.5. Cell proliferation.....   | 117        |
| 4.3.6. Ki67 expression.....  | 118        |
| 4.3.7. Cell viability .....  | 119        |
| 4.3.7.1. Cell viability assessment in acrylates-based microgels .....        | 119        |
| 4.3.7.2. Cell viability assessment in Cytodex 1-based microgels.....         | 120        |
| 4.3.8. Drug resistance in microgel cultures .....                            | 121        |
| 4.3.9. RNA extraction and RT-PCR.....  | 122        |
| 4.3.10. qPCR gene expression analysis.....                                   | 122        |
| 4.3.11. Statistical analysis and reproducibility .....                       | 123        |
| <b>4.4. Results and discussion .....</b>                                     | <b>124</b> |
| 4.4.1. Assembling of the 3D culture platform using acrylates-based microgels | 124        |

|  |            |
|--|------------|
| 4.4.2. Acrylates-based microgels allowed good cell proliferation of different MM cell lines .....          | 128        |
| 4.4.3. Drug resistance generation in acrylates-based microgels .....                                       | 136        |
| 4.4.3.1. Dexamethasone studies.....  | 137        |
| 4.4.3.2. Bortezomib studies .....  | 145        |
| 4.4.4. Scale down of microgel-based culture conditions for future personalized medicine applications ..... | 154        |
| 4.4.5. Assembling of the 3D culture platform using Cytodex 1-based microgels .....                         | 156        |
| <b>4.5.Conclusions .....</b>   | <b>161</b> |
| <br>   |            |
| <b>SECTION 3. GENERAL CONCLUSIONS AND FUTURE PERSPECTIVES _____</b>  | <b>135</b> |
| <b><i>Chapter 6.....</i></b>   | <b>167</b> |
| <b><i>General conclusions .....</i></b>  | <b>167</b> |
| <b><i>Chapter 7.....</i></b>   | <b>173</b> |
| <b><i>Future perspectives.....</i></b>   | <b>173</b> |
| <b><i>Chapter 8.....</i></b>   | <b>177</b> |
| <b><i>Contributions.....</i></b>   | <b>177</b> |
| <b>8.1.Publications in scientific journals .....</b>   | <b>177</b> |
| <b>8.2.International conferences .....</b>   | <b>179</b> |
| <b>8.3.National conferences .....</b>  | <b>182</b> |
| <b>8.4.Education related publications.....</b>   | <b>183</b> |
| <b><i>References.....</i></b>  | <b>185</b> |